$50 Million Commitment to Health Equity
Vertex and the Vertex Foundation are making a $50 million commitment to enhance clinical trial diversity, access to quality care, and education of our health care workforce.
Vertex Announces First Quarter 2022 Financial Results
Health Canada Grants Marketing Authorization for our Fourth Cystic Fibrosis (CF) Medicine for Eligible Children with CF Ages 6-11 Years Old
View our 2021 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2021.
Pain Program Update
We’ve announced Phase 2 data from two studies of an investigational small molecule for the potential treatment of acute pain.
Kidney Disease Program Update
Our APOL1-mediated kidney disease program moves into pivotal development